Agendia
Quick facts
Marketed products
- Dose dense AC followed by T + trastuzumab · Oncology
This is a chemotherapy regimen combining dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab (Herceptin) to treat HER2-positive breast cancer by killing cancer cells and blocking HER2 signaling. - PTH followed by dose dense AC of FEC · Oncology
This is a chemotherapy regimen combining paclitaxel/trastuzumab (PTH) followed by dose-dense doxorubicin/cyclophosphamide (AC) or 5-fluorouracil/epirubicin/cyclophosphamide (FEC) to treat HER2-positive breast cancer. - TAC chemotherapy · Oncology
TAC is a chemotherapy regimen combining docetaxel, doxorubicin, and cyclophosphamide to kill rapidly dividing cancer cells through multiple cytotoxic mechanisms. - TC chemotherapy · Oncology
TC chemotherapy is a combination regimen of docetaxel (Taxotere) and cyclophosphamide that disrupts microtubule dynamics and cross-links DNA to kill rapidly dividing cancer cells. - TCH chemotherapy · Oncology
TCH is a chemotherapy regimen combining docetaxel, carboplatin, and trastuzumab to kill cancer cells and target HER2-positive tumors.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: